Potent, selective, and orally active adenosine A2A receptor antagonists: Arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 5, 2007, Pages 1376-1380

  Neustadt, Bernard R ^a   Hao, Jinsong ^a   Lindo, Neil ^a   Greenlee, William J ^a   Stamford, Andrew W ^a   Tulshian, Deen ^a   Ongini, Ennio ^b   Hunter, John ^a   Monopoli, Angela ^b   Bertorelli, Rosalia ^b   Foster, Carolyn ^a   Arik, Leyla ^a   Lachowicz, Jean ^a   Ng, Kwokei ^a   Feng, Kung I ^a  

^a Departments of Chemical Research   (United States)

^b Schering Plough Research Institute   (Italy)

Author keywords

Adenosine A2A; Catalepsy; Parkinson's; Pyrazolo 4,3 e 1,2,4 triazolo 1,5 c pyrimidine

Indexed keywords

ADENOSINE A2A RECEPTOR ANTAGONIST; HALOPERIDOL; PIPERAZINE DERIVATIVE; SCH 420814; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALEPSY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; IN VIVO STUDY; NONHUMAN; RAT; RECEPTOR AFFINITY; STEADY STATE;

ADMINISTRATION, ORAL; ANIMALS; CATALEPSY; DISEASE MODELS, ANIMAL; PARKINSON DISEASE; PIPERAZINES; PYRIMIDINES; RATS; RECEPTOR, ADENOSINE A2A; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; TREATMENT OUTCOME;

HUMAN ECHOVIRUS 1; RATTUS;

EID: 33846903864     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.11.083     Document Type: Article

References (29)

1. Jacobson K.A., van Galen P.J.M., and Williams M. J. Med. Chem. 35 (1992) 4007
2. Muller C.E. Drugs of the Future 25 (2000) 1043
3. Schwarzschild M.A., Agnati L., Fuxe K., Chen J.-F., and Morelli M. Trends Neurosci. 29 (2006) 647
4. Bara-Himenez W., Sherzai A., Dimitrova T., Favit A., Bibbiani F., Gillespie M., Morris M.J., Mouradian M.M., and Chase T.N. Neurology 61 (2003) 293
5. Hauser R.A., Hubble J.P., and Truong D.D. Neurology 251 (2003) 297
6. Francis J.E., Cash W.D., Psychoyos S., Ghai G., Wenk P., Friedmann R.C., Atkins C., Warren V., Furness P., Hyun J.L., Stone G.A., Desai M., and Williams M. J. Med. Chem. 31 (1988) 1014
7. Sarges R., Howard H.R., Brown R.G., Lebel L.A., Seymour P.A., and Koe B.K. J. Med. Chem. 33 (1990) 2240
8. For recent examples of bicyclic systems, see:. Vu C.B., Pan D., Peng B., Sha L., Kumaravel G., Jin X., Phadke D., Engber T., Huang C., Reilly J., Tam S., and Petter R.C. Bioorg. Med. Chem. Lett. 14 (2004) 4831
9. Vu C.B., Shields P., Peng B., Kumaravel G., Jin X., Phadke D., Wang J., Engber T., Ayyub E., and Petter R.C. Bioorg. Med. Chem. Lett. 14 (2004) 4835
10. Dowling J.E., Vessels J.T., Haque S., Chang H.X., van Vloten K., Kumaravel G., Engber T., Jin X., Phadke D., Wang J., Ayyub E., and Petter R.C. Bioorg. Med. Chem. Lett. 15 (2005) 4809
11. Weiss S.M., Benwell K., Cliffe I.A., Gillespie R.J., Knight A.R., Lerpiniere J., Misra A., Pratt R.M., Revell D., Upton R., and Dourish C.T. Neurology 61 Suppl. 6 (2003) S101
12. Baraldi P.G., Manfredini S., Simoni D., Zapaterrra L., Zocchi C., Dionisotti S., and Ongini E. Bioorg. Med. Chem. Lett. 4 (1994) 2539
13. Baraldi P.G., Cacciari B., Spalutto G., Villatoro M.J.P., Zocchi C., Dionisotti S., and Ongini E. J. Med. Chem. 39 (1996) 1164
14. Ongini E. Drug Dev. Res. 42 (1997) 63
15. Baraldi P.G., Cacciari B., Spalutto G., Bergonzoni M., Dionisotti S., Ongini E., Varani K., and Borea P.A. J. Med. Chem. 41 (1998) 2126
16. Baraldi P.G., Fruttarolo F., Tabrizi M.A., Preti D., Romagnoli R., El-Kashef H., Moorman A., Varani K., Gessi S., Merighi S.K., and Borea P.A. J. Med. Chem. 46 (2003) 1229
17. Baraldi P.G., Tabrizi M.A., Bovero A., Avitabile B., Preti D., Fruttarolo F., Romagnoli R., Varani K., and Borea P.A. Eur. J. Med. Chem. 38 (2003) 367
18. This work was reported in part at the American Chemical Society 231st National Meeting (March 2006), paper MEDI 204.
19. Klötzer W., and Herberz M. Monats. Chem. 96 (1965) 1567 Also purchased from AstaTech, Inc
20. El Ashry E.S.H., El Kilany Y., Rashed N., and Assafir H. Adv. Heterocyclic Chem. 75 (2000) 79
21. Professor Andrew McPhail, private communication.
22. Morita S., Kitano K., Matsubara J., Ohtani T., Kawana Y., Otsubo K., and Uchida M. Tetrahedron 54 (1998) 4811
23. A detailed description of the adenosine receptor binding assays is provided in Bioorg. Med Chem. Lett. 2005, 15, 1333, footnote 11.
24. Myslobodsky M.S., Mintz M., and Kofman O. Pharmacol. Biochem. Behav. 15 (1981) 93
25. Pinna A., Volpini R., Cristalli G., and Morelli M. Eur. J. Pharmacol. 512 (2005) 157
26. Assay methodology described in:. Ongini E., Dionosotti S., Gessi S., Irenius E., and Fredholm B.B. Naunyn Schmiederbergs Arch. Pharmacol. 359 (1999) 7
27. Assay methodology described in:. Jacobson K.A., and Ji X.D. Drug Design Discov. 16 (1999) 217
28. 1; NE uptake: AT1 and 2; bradykinin B2; CGRP; CCK1 and 2; CB1 and 2; C5a; CCR2, 3, 6, and 7; CXCR3; dopamine uptake; ET-A and B; FPR1; EGF; galanin and GALR2; glucagon; H3; IL-6; LTB4 and D4; melanocortin; motilin; muscarinic M1-M5; NK1-3; NPY1-5; prostaglandin EP1 and IP; 5-HT 1A, 2C, 6, and 7; progesterone; VIP; and V1 a.
29. A single measurement at pH 7.4 gave solubility below 10 ng/mL.